Here at Cashinbis we pride ourselves in covering global advancements in the medical cannabis and hemp spaces. We get press releases from all over the world, updating us on legalization, upcoming legislation, and new applications for medical treatments. This week it appears that Brazil has taken another positive step in the advancement of medical hemp applications.
The government of Brazil announced that it has approved Medical Marijuana Inc.’s flagship RSHO (Real Scientific Hemp Oil) product for treatment of chronic pain conditions. This is especially notable when considering that this is now the third indication for the importation of RSHO. As seen on ABC 7 News, the first two indications to be approved for the import of RSHO by the Brazilian government are epilepsy and Parkinson’s disease.
“We sincerely commend the Brazilian government for allowing CBD hemp oil to be imported as a third indication. With the availability of non-psychoactive hemp CBD oil in Brazil, individuals of all ages can stand to benefit from this all-natural supplement.” – Dr. Stuart Titus – CEO of Medical Marijuana Inc.
Chronic Pain By The Numbers
It is reported that chronic pain affects roughly 100 million U.S. adults and as much as 1.5 Billion people across the globe. Perhaps even more alarming is that this total amounts to more than heart disease, cancer and diabetes combined. Additionally, chronic pain costs the United States alone up to $635 billion each year in medical treatment and lost productivity.
The idea that medical hemp or medical cannabis can help those who suffer from chronic pain is certainly not a groundbreaking notion to those within the medical cannabis community. In fact, even the American government, despite classifying the cannabis plant as a Schedule 1 substance (meaning the plant has no medical application), acknowledges the potential medical benefits in a United States patent.
United States Patent On Cannabinoids
U.S. Department of Health and Human Service’s patent number 6630507 states, “Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases.”
The patent also states, “Non-Psychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.”
About Chronic Pain
A recent market survey report indicates that the global pain management market is projected to reach $60 billion (USD) this year. The National Institutes of Health website states, “Acute pain starts quickly and lasts less than 6 weeks. The site continues, “Chronic pain lasts for more than 3 months and is much less common than acute pain.”
Facts about chronic pain:
- Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees.
- 3-4.5% of the world’s population suffers from neuropathic (nerve related) pain, with the incidence rate proportionate to age.
- Other health problems accompany chronic pain including: fatigue, sleep disturbance, decreased appetite, and mood changes and may affect people’s ability to participate in daily tasks.
Traditional Medicines Can Be Dangerous
Pain management medications are coming under increased scrutiny, as is evidenced by U.S. FDA warnings on the safety of nonsteroidal anti-inflammatory drugs (NSAIDs) from July 2015. NSAIDs have a tendency toward injury of the mucosa of the GI tract causing ulceration, bleeding, etc. Labels of these medications must now show an increased risk of heart attack or stroke.
“Research has shown that cannabis is non-addictive. In contrast, this is extremely important to consider when researching just how addictive prescription pain medications can be.” – Dr. Stuart Titus – CEO of Medical Marijuana Inc.
- Prescription drug abuse in the U.S. is the fastest-growing drug problem.
- Nearly one-third of people aged 12 and over who used drugs for the first time in 2009 in the U.S. began by using a prescription drug non-medically.
- Over 70 percent of people in the U.S. who abused prescription pain relievers got them from friends or relatives.
In a report published by JAMA Internal Medicine, data indicates that in U.S. states with access to medical cannabis to manage chronic pain and other conditions, the annual number of deaths from prescription drug overdose has been reduced by 25 percent.
What is Real Scientific Hemp Oil (RSHO)?
Medical Marijuana, Inc.’s cannabidiol (CBD) hemp oil is derived from the mature stalk of the hemp plant and is considered a food nutrient delivering the benefits of cannabinoids without the psychotropic/euphoric effects of THC. RSHO is non-GMO and contains no pesticides, herbicides or heavy metals. Before becoming a finished product, RSHO goes through multiple quality tests by top cannabis industry and food laboratories.
What This Means For The People Of Brazil
Today, on a case-by-case basis, residents of Brazil who have a government-recognized medical indication and want access to RSHO™ hemp oil products, may do so with a doctor’s prescription and approved import documentation from ANVISA. The government agency issued a statement on its website and also explains how to apply for an import certificate.
Imagine that. A government that recognizes a nationwide health problem exists and then looks for a solution to solve that problem. Then, once they find it, they actually embrace the medicinal values of the treatment rather than constantly push the issue to the back burner on the false merit of ‘more research and time’.
If we were to apply standard logic, one would think that if the United States federal government didn’t believe in the therapeutic value of medical cannabinoids then they wouldn’t have gone to the trouble to obtain the government patent to protect it. One would think.
What do you think about this new approval from the Brazilian government? Do you have a press release you would like to share with us? Email us at firstname.lastname@example.org.